This priority review designation for sevabertinib in previously treated HER2-mutant non–small cell lung cancer is supported by data from the phase 1/2 SOHO-01 study.

Younger lung cancer patients frequently have targetable biomarkers, allowing for personalized therapies that can improve survival rates. Targeted therapies differ from traditional treatments, focusing ...

Researchers are trying to better understand how co-mutations and PD-L1 expression impact response to single-agent KRAS G12C ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated ...

These biomarkers could revolutionize lung cancer screening by improving accuracy and risk stratification. To gather further insights into the realms of biomarker reliability and utility, we welcome ...

A biomarker could help identify patients with lung cancer who are most likely to benefit from treatment with AstraZeneca and Daiichi Sankyo's TROP2-directed drug datopotamab deruxtecan (Dato-DXd).

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

For many years, ... Feb. 6, 2025 — Scientists have created a new low-cost, fast response sensor to detect lung cancer biomarkers, paving the way for the development of screening devices to spot ...

Scientists have created a new low-cost, fast response sensor to detect lung cancer biomarkers, paving the way for the development of screening devices to spot the disease even before symptoms occur.

Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert ...